Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2012

01-11-2012

Dabigatran and left atrial appendage thrombus

Authors: Alejandro Vidal, Gabriel Vanerio

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2012

Login to get access

Abstract

A 59-year-old white woman with previous history of arterial hypertension consulted because of palpitations. Atrial fibrillation of uncertain duration was diagnosed. She was not receiving anticoagulants. A trans-esophageal echocardiogram was performed, and a large left atrial appendage thrombus was detected. A strategy of rate control and anti-vitamin K treatment was started. On the subsequent days, we could not reach therapeutic INRs. Therefore, it was decided to stop warfarin and initiate dabigatran. We describe the evolution of the patient, the thrombus resolution, and a successful electrical cardioversion. In our comments, we summarize the natural history of left atrial thrombus, both with and without anticoagulant therapy. We also discuss the differences between warfarin and dabigatran.
Literature
1.
go back to reference Prasad V, Kaplan RM, Passman RS (2012) New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 33:199–208PubMedCrossRef Prasad V, Kaplan RM, Passman RS (2012) New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc Dis. 33:199–208PubMedCrossRef
2.
3.
go back to reference Wolfram O, Hammwoehner M, Gramley F, Goette A (2011) Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer? Curr Vasc Pharmacol 9:350–357PubMedCrossRef Wolfram O, Hammwoehner M, Gramley F, Goette A (2011) Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer? Curr Vasc Pharmacol 9:350–357PubMedCrossRef
4.
go back to reference Broukhim M, Halperin JL (2011) Stroke prevention in the high-risk atrial fibrillation patient: Medical management. Curr Cardiol Rep. 13:9–17PubMedCrossRef Broukhim M, Halperin JL (2011) Stroke prevention in the high-risk atrial fibrillation patient: Medical management. Curr Cardiol Rep. 13:9–17PubMedCrossRef
5.
go back to reference Medi C, Hankey GJ, Freedman SB (2010) Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 41:2705–2713PubMedCrossRef Medi C, Hankey GJ, Freedman SB (2010) Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 41:2705–2713PubMedCrossRef
6.
go back to reference Santos-Gallego CG, Bayón J, Badimón JJ (2010) Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med. 12:274–291PubMedCrossRef Santos-Gallego CG, Bayón J, Badimón JJ (2010) Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med. 12:274–291PubMedCrossRef
7.
go back to reference Savelieva I, Bajpai A, Camm AJ (2007) Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 39:371–391PubMedCrossRef Savelieva I, Bajpai A, Camm AJ (2007) Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 39:371–391PubMedCrossRef
8.
go back to reference Thambidorai SK, Murray RD, Parakh K, Shah TK, Black IW, Jasper SE, Li J, Apperson-Hansen C, Asher CR, Grimm RA (2005) ACUTE investigators. utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol 96:935–941PubMedCrossRef Thambidorai SK, Murray RD, Parakh K, Shah TK, Black IW, Jasper SE, Li J, Apperson-Hansen C, Asher CR, Grimm RA (2005) ACUTE investigators. utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol 96:935–941PubMedCrossRef
9.
go back to reference Odum LE, Cochran KA, Aistrope DS, Snella KA (2012) The CHADS(2) versus the new CHA(2) DS(2) -VASc scoring systems for guiding Antithrombotic treatment of patients with Atrial Fibrillation: Review of the Literature and Recommendations for Use. Pharmacotherapy 32:285–296PubMedCrossRef Odum LE, Cochran KA, Aistrope DS, Snella KA (2012) The CHADS(2) versus the new CHA(2) DS(2) -VASc scoring systems for guiding Antithrombotic treatment of patients with Atrial Fibrillation: Review of the Literature and Recommendations for Use. Pharmacotherapy 32:285–296PubMedCrossRef
10.
go back to reference Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kübler W (1989) Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 31:363–369PubMed Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kübler W (1989) Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 31:363–369PubMed
11.
go back to reference Roijer A, Eskilsson J, Olsson B (2000) Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. Eur Heart J 21:837–847PubMedCrossRef Roijer A, Eskilsson J, Olsson B (2000) Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion. Eur Heart J 21:837–847PubMedCrossRef
12.
go back to reference Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, Wallentin L, Van de Werf FJ (2006) age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from assessment of the Safety and Efficacy of a new Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 152(684):e1–e9PubMed Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, Wallentin L, Van de Werf FJ (2006) age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from assessment of the Safety and Efficacy of a new Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 152(684):e1–e9PubMed
13.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S, et al., and the RE-LY Steering Committee and Investigators(2009) Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med361:1139-1151 Connolly SJ, Ezekowitz MD, Yusuf S, et al., and the RE-LY Steering Committee and Investigators(2009) Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med361:1139-1151
14.
go back to reference Di Nisio M, Middeldorp S, Büller HR (2005) Direct thrombin inhibitors. N Engl J Med 353:1028–1040PubMedCrossRef Di Nisio M, Middeldorp S, Büller HR (2005) Direct thrombin inhibitors. N Engl J Med 353:1028–1040PubMedCrossRef
15.
go back to reference Clouse LH, Comp PC (1986) The regulation of hemostasis: The protein C system. N Engl J Med 314:1298PubMedCrossRef Clouse LH, Comp PC (1986) The regulation of hemostasis: The protein C system. N Engl J Med 314:1298PubMedCrossRef
16.
go back to reference Weinreich DJ, Burke JF, Pauletto FJ (1984) Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Intern Med 100:789–794PubMed Weinreich DJ, Burke JF, Pauletto FJ (1984) Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Intern Med 100:789–794PubMed
17.
go back to reference Banner DW, Hadvary P (1993) Inhibitor binding to thrombin: X-ray crystallographic studies. Adv Exp Med Biol 340:27–33PubMed Banner DW, Hadvary P (1993) Inhibitor binding to thrombin: X-ray crystallographic studies. Adv Exp Med Biol 340:27–33PubMed
18.
go back to reference Hauptmann J, Sturzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93:203–241PubMedCrossRef Hauptmann J, Sturzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93:203–241PubMedCrossRef
19.
go back to reference Xiao Z, Theroux P (1998) Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97:251–256PubMedCrossRef Xiao Z, Theroux P (1998) Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97:251–256PubMedCrossRef
20.
go back to reference Sarich TC, Wolzt M, Eriksson UG et al (2003) Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 41:557–564PubMedCrossRef Sarich TC, Wolzt M, Eriksson UG et al (2003) Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 41:557–564PubMedCrossRef
Metadata
Title
Dabigatran and left atrial appendage thrombus
Authors
Alejandro Vidal
Gabriel Vanerio
Publication date
01-11-2012
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0747-1

Other articles of this Issue 4/2012

Journal of Thrombosis and Thrombolysis 4/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.